Drugs / Recombinant Hepatitis B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04071379 | Oct 2020 → Apr 2021 | — | PT Bio Farma | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-11-13 | PT Bio Farma | Regulatory Bio Farma Daftarkan Pentabio ke WHO co.id ↗
PT. Bio Farma (Company) is registering a vaccine product of Pentabio which is the combination of Diphtheria, Tetanus, Pertusiss, recombinant hepatitis B, Haemophilus Influenza type B to the World Health Organization (WHO). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-11-13 | PT Bio Farma | Bio Farma Daftarkan Pentabio ke WHO co.id ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Hepatitis B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04071379 ↗ |
| Known as | Recombinant Hepatitis B (Bio Farma) | “Recombinant Hepatitis B (Bio Farma) + Pentabio (Bio Farma)” NCT04071379 ↗ |